CIK 0001515673
- Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272546083
- Phone
- +1 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $127,561
- in 3 filings, $17K under 10b5-1 plans
Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-01 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +7,400 | 7,400 | ||
| 2022-03-01 | Huang Dennis Karl See Remarks | Sale | −3,234 | $66.62 | $215K | 36,914 |
| 2022-03-01 | Huang Dennis Karl See Remarks | Grant or award | +14,000 | 51,040 | ||
| 2022-03-01 | Huang Dennis Karl See Remarks | Grant or award · Stock Option (Right to Buy) | +24,900 | 24,900 | ||
| 2022-03-01 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale | −2,886 | $66.62 | $192K | 25,472 |
| 2022-03-01 | Parschauer Karah Herdman EVP and Chief Legal Officer | Grant or award | +14,000 | 39,578 | ||
| 2022-03-01 | Parschauer Karah Herdman EVP and Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +24,900 | 24,900 | ||
| 2022-03-01 | Kassberg Thomas Richard CBO & EVP | Sale | −2,374 | $66.62 | $158K | 213,840 |
| 2022-03-01 | Kassberg Thomas Richard CBO & EVP | Grant or award | +14,000 | 227,840 | ||
| 2022-03-01 | Kassberg Thomas Richard CBO & EVP | Grant or award · Stock Option (Right to Buy) | +24,900 | 24,900 | ||
| 2022-03-01 | Bedrosian Camille L EVP and Chief Medical Officer | Sale | −2,821 | $66.62 | $188K | 33,938 |
| 2022-03-01 | Bedrosian Camille L EVP and Chief Medical Officer | Grant or award | +14,000 | 47,938 | ||
| 2022-03-01 | Bedrosian Camille L EVP and Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +24,900 | 24,900 | ||
| 2022-03-01 | KAKKIS EMIL D President & CEO | Shares withheld for taxes | −12,162 | $67.37 | $819K | 582,185 |
| 2022-03-01 | KAKKIS EMIL D President & CEO | Grant or award | +52,041 | 634,226 | ||
| 2022-03-01 | KAKKIS EMIL D President & CEO | Grant or award · Stock Option (Right to Buy) | +92,360 | 92,360 | ||
| 2022-01-30 | Bedrosian Camille L EVP and Chief Medical Officer | Sale | −1,657 | $66.30 | $110K | 36,759 |
| 2021-10-14 | Bedrosian Camille L EVP and Chief Medical Officer | Sale | −359 | $81.14 | $29K | 38,416 |
| 2021-10-14 | Harris Erik EVP & Chief Commercial Officer | Sale | −303 | $81.14 | $25K | 25,030 |
| 2021-10-14 | Huang Dennis Karl EVP & Chief Tech Ops Officer | Sale | −358 | $81.14 | $29K | 40,148 |
Page 17 of 21 · 410 trades